## Maytham H Hussein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/441592/publications.pdf

Version: 2024-02-01

759233 940533 17 490 12 16 citations h-index g-index papers 17 17 17 754 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Unique mechanistic insights into pathways associated with the synergistic activity of polymyxin B and caspofungin against multidrug-resistant Klebsiella pneumoniae. Computational and Structural Biotechnology Journal, 2022, 20, 1077-1087.	4.1	10
2	Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study. Journal of Visualized Experiments, 2022, , .	0.3	2
3	Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study. Pharmaceutics, 2022, 14, 786.	4.5	11
4	Synthesis and structureâ^'activity relationships of teixobactin. Annals of the New York Academy of Sciences, 2020, 1459, 86-105.	3.8	26
5	Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens. Computational and Structural Biotechnology Journal, 2020, 18, 2247-2258.	4.1	17
6	The Antimicrobial Activity of Cannabinoids. Antibiotics, 2020, 9, 406.	3.7	64
7	Effective Strategy Targeting Polymyxin-Resistant Gram-Negative Pathogens: Polymyxin B in Combination with the Selective Serotonin Reuptake Inhibitor Sertraline. ACS Infectious Diseases, 2020, 6, 1436-1450.	3.8	20
8	The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study. MSystems, 2020, 5, .	3.8	33
9	Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight, 2020, 5, .	5.0	159
10	The impact of backbone N â€methylation on the structureâ€activity relationship of Leu 10 â€teixobactin. Journal of Peptide Science, 2019, 25, e3206.	1.4	6
11	Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	28
12	ePS6.07 Synergistic killing of polymyxin B in combination with the CFTR potentiator ivacaftor against polymyxin-resistant Pseudomonas aeruginosa isolates from the cystic fibrosis paediatric lung: an untargeted metabolomics study. Journal of Cystic Fibrosis, 2019, 18, S55.	0.7	0
13	Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa. Computational and Structural Biotechnology Journal, 2018, 16, 587-599.	4.1	19
14	A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant <i>Klebsiella pneumoniae</i> Strains. ACS Infectious Diseases, 2018, 4, 1692-1704.	3.8	15
15	Lipidomic Analysis of the Outer Membrane Vesicles from Paired Polymyxin-Susceptible and -Resistant Klebsiella pneumoniae Clinical Isolates. International Journal of Molecular Sciences, 2018, 19, 2356.	4.1	23
16	From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs―Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Microbial Drug Resistance, 2017, 23, 640-650.	2.0	45
17	A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles. Journal of Biomedical Nanotechnology, 2017, 13, 447-457.	1.1	12